X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The FDA's Fast Track designation is designed for AIC100 facilitate development and expedite review of drug candidates to treat serious conditions and address an unmet medical need.
Lead Product(s): AIC100
Therapeutic Area: Oncology Product Name: AIC100
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: AffyImmune Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse.
Lead Product(s): AKE-1018
Therapeutic Area: Neurology Product Name: AKE-1018
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Akelos
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acne.
Lead Product(s): HT-003
Therapeutic Area: Dermatology Product Name: HT-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
